Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclo Therapeutics Inc (CYTH)

Cyclo Therapeutics Inc (CYTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cyclo Therapeutics Inc 6714 NW 16TH STREET SUITE B GAINESVILLE FL 32653 USA

www.cyclotherapeutics.com Employees: 8 P: 386-418-8060 F: 321-244-8351

Description:

Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. Cyclo Therapeutics Inc., formerly known as CTD Holdings Inc., is based in ALACHUA, Fla.

Key Statistics

Overview:

Market Capitalization, $K 21,001
Enterprise Value, $K 11,751
Shares Outstanding, K 28,768
Annual Sales, $ 1,080 K
Annual Net Income, $ -20,060 K
Last Quarter Sales, $ 230 K
Last Quarter Net Income, $ -8,830 K
EBIT, $ -24,680 K
EBITDA, $ -24,660 K
60-Month Beta -0.38
% of Insider Shareholders 29.78%
% of Institutional Shareholders 68.55%
Float, K 20,201
% Float 70.22%
Short Volume Ratio 0.03

Growth:

1-Year Return -38.66%
3-Year Return -86.17%
5-Year Return 0.00%
5-Year Revenue Growth 6.93%
5-Year Earnings Growth 75.40%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.26 on 11/14/24
Next Earnings Date 11/12/24
Earnings Per Share ttm -0.85
EPS Growth vs. Prev Qtr -23.81%
EPS Growth vs. Prev Year 10.34%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CYTH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -307.16%
Profit Margin % -1,857.41%
Debt/Equity 0.00
Price/Sales 18.69
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.47
Interest Coverage -1.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar